ABSTRACT Purpose Biometals such as zinc and copper have been shown to affect tight junction expression and subsequently bloodbrain barrier (BBB) integrity. Whether these biometals also influence the expression and function of BBB transporters such as P-glycoprotein (P-gp) however is currently unknown. Methods Using the immortalised human cerebral microvascular endothelial (hCMEC/D3) cell line, an in-cell western assay (alongside western blotting) assessed relative P-gp expression after treatment with the metal ionophore clioquinol and biometals zinc and copper. The fluorescent P-gp substrate rhodamine-123 was employed to observe functional modulation, and inductively coupled plasma mass spectrometry (ICP-MS) provided information on biometal trafficking. Results A 24-h treatment with clioquinol, zinc and copper (0.5, 0.5 and 0.1 μM) induced a significant upregulation of P-gp (1.7-fold) assessed by in-cell western and this was confirmed with western blotting (1.8-fold increase). This same treatment resulted in a 23% decrease in rhodamine-123 accumulation over a 1 h incubation. ICP-MS demonstrated that while t8his combination treatment had no effect on intracellular zinc concentrations, the treatment significantly enhanced bioavailable copper (4.6-fold). Conclusions Enhanced delivery of copper to human brain microvascular endothelial cells is associated with enhanced expression and function of the important efflux pump P-gp, which may provide therapeutic opportunities for P-gp modulation.
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INTRODUCTION
The blood-brain barrier (BBB) is a dynamic interface which separates the brain parenchyma from the systemic circulation, and serves to protect the brain from xenobiotic insult, whilst simultaneously permitting a high influx of central nervous system (CNS)-essential nutrients (1) . To facilitate these needs, a large range of transporter proteins are expressed within the specialised endothelial cells that line the lumen of the BBB (2). Over decades of transporter characterisation research, one of these transporters, P-glycoprotein (P-gp), has emerged as of particular interest in both drug discovery efforts and the pathophysiology of some disease states. P-gp is expressed on the luminal face of the brain endothelium (3) , where from the lipid milieu of plasma membrane bilayer it actively effluxes xenobiotics (4), pharmaceuticals and endogenously produced substrates. The existence of P-gp at the BBB has hindered the success of many attempts at brain-targeted drug discovery, whereby many otherwise pharmacologically sound molecular entities are denied CNS access, by virtue of P-gp activity (5) . P-gp is also associated with a pathological role in tumorigenesis, where sustained upregulation of P-gp can be a key defensive feature, preventing cellular access of chemotherapeutic agents (6) . It is also becoming increasingly apparent that P-gp plays a pivotal role in the prevention of some disease states, such as that of Alzheimer's disease (AD) (7) . In AD, the noxious amyloid-beta (Aβ) which is thought to be responsible for downstream neurodegeneration, is steadily produced by neurons, and cleared from the brain by several mechanisms to prevent accumulation (8) . Active efflux of Aβ across bloodbrain barrier (BBB) represents one of the main clearance mechanisms of Aβ from the brain parenchyma (9) (10) (11) , and P-gp appears to play a role in both brain-to-blood efflux of Aβ, as well as in preventing blood-borne Aβ from diffusing or endocytosing back into the brain (12, 13) . Although the timelines and causes of the observed reductions are not yet fully understood (7), waning P-gp expression has been observed within the pathophysiological cascade of AD, which likely corresponds to a reduced capacity for healthy Aβ trafficking (14, 15) . Thus it has been suggested that approaches to increase the expression or activity of P-gp by pharmacological means may aid in the treatment of AD, by restoring BBB efflux mechanisms of Aβ trafficking, and subsequently halting the accumulation of Aβ within the CNS (16, 17) .
Since P-gp activity is of such interest to CNS-drug access, oncology and AD research, understanding the various biological inputs for P-gp expression is of importance. One potential mechanism for upregulating P-gp is the redistribution of biometals within brain endothelial cells, which has been shown previously to contribute to BBB integrity in a positive manner. Whilst this area is relatively unexplored, some encouraging studies have been conducted. Zinc ions have been shown for example to protect BBB diffusion integrity in juvenile rats (18) , and elsewhere Zn 2+ was demonstrated as essential in maintaining cultured porcine endothelial barrier function (19) . More recently, additional studies have also shown that in primary brain microvascular endothelial cells (BMECs), copper at low concentrations increases cell viability and proliferation (20) , and that copper alongside vascular endothelial growth factor is a stimulatory driver of angiogenesis in the rat vascular endothelium (21) . Thus it was hypothesised that enhanced delivery of zinc or copper ions to human BMECs might facilitate the upregulation of the key AD-related efflux transporter, P-gp.
A set of pharmacological tools available for enhancing the delivery of biometals to cell interiors are a class of drugs known as the ionophores. One of the early ionophores, clioquinol (CQ), has been shown previously to enhance the delivery of both copper and zinc ions across cell membranes and into the cytosol of neurons, where these ions are then freed to influence cell signalling pathways in a positive manner, with respect to AD (22) . Additionally, a nine week treatment of CQ in APP2576 transgenic mice (a mouse model of familial AD that overexpresses a mutant form of amyloid precursor protein, resulting in elevated levels of both soluble and plaque entombed Aβ), produced a 49% reduction in Aβ brain deposition (23) . Since CQ was able to ameliorate the AD phenotype in this mouse model via the redistribution of metal ions within the brain, it is possible that CQ may have the potential to traffic plasma-bound biometals in or out of the brain endothelium en route to the brain, with the potential of influencing BBB transporter expression profiles along the way. Therefore, it was hypothesised that by enhancing brain endothelial cell levels of Cu 2+ and Zn 2+ , CQ may be able to upregulate P-gp expression and function at the BBB. Herein we used a recently developed and validated in-cell western (ICW) approach, which provides higher throughput and is less labour and consumable intensive than other methods such as western blotting (24) , to assess whether CQ can shuttle metal ions into immortalised human cerebral microvascular endothelial cells (hCMEC/D3), resulting in upregulation of P-gp expression and function. The outcomes of these studies have the potential to provide insight into fundamental mechanisms governing the regulation of the important BBB efflux transporter P-gp, with implications for both CNS drug delivery and Aβ clearance from the brain.
MATERIALS AND METHODS
Materials
4′,6-diamidino-2-phenylindole (DAPI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent), triton X-100, Tween-20, paraformaldehyde, sodium chloride, potassium chloride, disodium phosphate, rhodamine-123 (R123), potassium phosphate and Corning black polystyrene TC-treated 96 well plates were all purchased from Sigma Aldrich (St Louis, MO). TRIS buffer salt (TRIZMA base), sodium dodecyl sulphate (SDS), ammonium persulfate (APS), N,N,N′,N′-tetramethylethylenediamine ( T E M E D ) , t r y p a n b l u e , g l y c e r o l , T r y p s i nethylenediaminetetraacetic acid (EDTA) solution 0.25% in Hank's balanced saline solution (HBSS) and Dulbecco's sterile phosphate buffered saline (PBS) were all purchased from Sigma Life Sciences (St Louis, MO). 40% acrylamide/bis solution was purchased from Bio-Rad Laboratories (Hercules, CA). Valspodar (PSC833) was a gift from Novartis (Basel, Switzerland). Odyssey PBS blocking buffer and the goat-antimouse secondary antibody were both purchased from Millennium Science (Mulgrave, Victoria, Australia). cOmplete Tablets Mini EASY pack protease inhibitors were purchased from Roche Diagnostics GmbH (Mannheim, Germany). Nitrocellulose membrane (0.2 μm pore-sized) was purchased from GE Life Sciences (Rydalmere, New South Wales, Australia). The C219 P-glycoprotein antibody was purchased from Australian Biosearch (Balcatta, Western Australia, Australia). Corning Costar transparent 96 well plates were purchased from Invitro (Noble Park North, Victoria, Australia). Fluorescein was purchased from Vector laboratories (Burlingame, CA). Black polystyrene ViewPlateR-96 F TC from Perkin Elmer, the Pierce IP lysis buffer and the BCA protein assay kit were all purchased from Thermo Fisher Scientific (Scoresby, VIC, Australia). Both Clonetics EBM-2 basal media and Clonetics EGM-2 single quots growth factor kits were purchased from Lonza (Walkersville, MD). Collagen type I was purchased from Corning Discovery Labware (Bedford, MD). Heat inactivated fetal bovine serum (FBS) was purchased from Life Technologies (Mulgrave, Victoria, Australia). 6 and 96-well plates were purchased from Corning Incorporated (Corning, NY). The purified water used in all experiments was obtained from a Millipore unit and filtered through a Q-pod fitted with a 0.22 μm membrane filter.
Seeding/Splitting of the hCMEC/D3 Cell Line
The immortalized human brain microvascular endothelial cell line (hCMEC/D3) was generously provided by Dr. Pierre-Olivier Couraud (INSERM, Paris, France). The EBM2 media which was used for all cell culture experiments, was prepared by supplementation with the following prior to commencement of the studies: 0.01% (v/v) ascorbic acid, 0.01% (v/v) gentamicin/amphotericin, 0.01% (v/v) hydrocortisone, 0.025% (v/v) epidermal growth factor, 0.025% (v/ v) insulin-like growth factor, 0.025% (v/v) vascular endothelial growth factor, 0.1% (v/v), b-splice variant fibroblast growth factor, 10 mM HEPES, and 1% (v/v) penicillin/streptomycin and 2.5% (v/v) FBS. Vials of the hCMEC/D3 cell line were kept cryogenically frozen in liquid nitrogen in a solution comprised of 5% (v/v) DMSO in FBS solution. 1 mL vials containing approximately 2 million cells were dispensed into T-75 flasks containing 14 mL of EBM2 media, which had been precoated with 3 mL of a 0.1 mg/mL solution of Collagen type I and incubated for 1 h, before being washed with 10 mL of PBS to remove excess collagen. 2 h after seeding of the hCMEC/D3 cells, the initial media was aspirated off and the cells washed twice with warm PBS, before being replaced with fresh and warm EBM2 media. The media was then changed every 2 days until the flasks reached approximately 90-100% confluency, at which point they were split into new flasks or plates for subsequent experiments. All experiments involving cells being treated with CQ and/or metal ions Zn 2+ and Cu
2+
, involved the following preparation: cells were left to grow in EBM2 growth media until they had reached 70-80% confluency. At the commencement of treatment, in order to remove trace FBS from wells and thus prevent extensive protein binding by CQ, the media was always removed and the cells were rinsed twice with PBS, before the addition of FBS-free EBM2 media with or without CQ and/or Zn 2+ and Cu
, in which the cells were incubated until the experimental endpoint. The cells were always stored in an incubator that was kept continuously at 37°C, with an air composition of 95% O 2 and 5% CO 2 . All experiments performed using the hCMEC/D3 cell line occurred between passage 30 to 35. and CuCl 2 at increasing concentrations first individually, and in subsequent experiments, in combination. The 96-well plates were then returned to the incubator for 24 h, after which, the plates were transported to a temperature and humidity controlled chamber housing a microscope and camera for morphological assessment. The microscope used was the Nikon Ti-E from Nikon, Japan. The camera used to generate the images was a Photometrics Coolsnap Myo from Photometrics, USA. The 10 x objective lens used was Version 3.22 from Nikon. One image per treatment well was captured before all treatment/media solutions were discarded, and the cells were washed twice with 160 μL of warm PBS. All wells were then treated with 160 μL of FBS free EBM2 media which additionally contained 6.25% (v/v) of an 8 mg/mL MTT reagent solution and then re-incubated for a further 4 h. After the 4 h incubation with the MTT reagent, the solution was aspirated off and 150 μL of DMSO was added to each well. The plates were then agitated for 30 s and then incubated with DMSO for a further 30 min. Again the plates were shaken for 30 s, and then absorbance at 540 nm was recorded on a Perkin Elmer absorbance spectrophotometer (Waltham, MA). Blank samples which had undergone all the above procedures except in the absence of cells were also present on the plate, an average of which was taken and subtracted from each individual reading recorded. The absorbance values were then normalized against the average of the control values, to be expressed comparatively as % viability when compared to the control group. Statistical comparisons of the datasets was performed using Dunnett's multiple comparisons test.
Identification of
Influence of CQ/Zn
2+
/Cu
Combinations on P-gp Expression Using an In-Cell Western Approach hCMEC/D3 cells were seeded onto 96-well collagen-coated plates at a density of 30,000 cells/cm 2 and left to grow in 150 μL of EBM2 growth media until they had reached 70-80% confluency. Cells were then treated with individual and combinatorial treatments of CQ, ZnCl 2 and CuCl 2 in FBS free media for 24 h, after which the treatment solutions were discarded, and the expression of P-gp quantified by the previously reported ICW technique (24) . Briefly, 150 μL of fixing solution (4% (w/v) paraformaldehyde in PBS) was transferred to each well, and the plate was left at room temperature for 20 min. The fixing solution was then discarded and cells were rinsed four times with 200 μL of cell permeabilisation solution (0.1% w/v Triton X-100 in PBS) under mild shaking. A final rinse using 210 μL of PBS was included to remove the detergent. Next, 150 μL of Licor PBS blocking buffer was added to each well and the plate was left to stir for 1 h at room temperature. The PBS blocking buffer solution was then removed, and 50 μL of PBS blocking buffer solution containing either a 1:50 dilution of the C219 P-gp antibody or no additional reagents (to be later used as secondary antibody controls) was added. The plate was then left overnight on gentle agitation at 4°C. The following day, each well was rinsed again four times with 200 μL of Tween washing solution (0.1% (v/v) Tween-20 in PBS, (PBS-T)). After removal of the last rinse, each well received 50 μL of PBS blocking buffer containing 0.5% (v/v) Tween-20, 1 μg/mL DAPI, and a 1:2000 dilution of Licor goat-anti-mouse (secondary) antibody. During secondary antibody incubation the plate was wrapped in aluminium foil and agitated gently at room temperature for 1 h. After this final incubation the plate was subjected to seven more 5 min rinses with 200 μL of PBS-T in each well, and the final two of these rinses using PBS to remove residual surfactant. The plate was then scanned on an Odyssey imager using the 'microplate2' setting with a 3 mm focus offset and the scan intensity of the 800 channel set to 5. After scanning, an ICW grid was applied to the obtained image within the Odyssey software, and the integrated intensity of IR signal from each well was then exported. The average of the IR signal of control wells that had not received P-gp primary antibody incubation was calculated and subtracted from all sample wells, to remove signal coming from non-specific binding of secondary antibody. The plate was then scanned in a Perkin Elmer fluorescence spectrophotometer with an excitation/emission wavelengths of 358 and 461 nm respectively. Wells treated only with collagen were used to calculate fluorescent background and subtracted from all other wells to discount any non-specific fluorescence. The remaining P-gp signal of treatment wells was then divided by the remaining DAPI signal, and finally expressed as fold change compared to the average of the control wells (not dissimilar to WB), according to Eq. 1:
where IR t = the IR signal from treatment wells; IR b = the infra-red signal from control wells treated with secondary antibody only (P-gp signal background subtraction); F t = the fluorescence signal from treatment wells; F b = the fluorescence signal from empty wells containing collagen only (DAPI background subtraction); IR c = the IR signal from control wells; F c = the fluorescence signal from control wells and n = the number of control replicates.
Confirmation of CQ/Zn
Mediated Upregulation of P-gp Using Western Blotting hCMEC/D3 cells were seeded onto 6-well collagen-coated plates at a density of 30,000 cells/cm 2 and left to grow in 2 mL of EBM2 growth media until they had reached 70-80% confluency. Cells were then treated with CQ, ZnCl 2 and CuCl 2 (0.5, 0.5 and 0.1 μM) in FBS free media for 24 h. Immediately after the 24 h incubation period, treatment solutions were discarded and to each well, 200 μL of a solution containing a 6:1 ratio of Pierce IP lysis buffer and a 7×-concentrated solution of cOmplete Tablets Mini EASY pack protease inhibitors, was dispensed into each well. Cells were then lysed in this solution for 15 min at 4°C, after which each well was scraped to ensure full detachment of cells. The solution from each well was transferred to a pre-cooled Eppendorf tube and spun at 14,000 rcf for 5 min before supernatant collection and protein content analysis via the Pierce BCA protein assay kit using bovine serum albumin (BSA) as a standard. Western blotting was carried out by loading a 10% acrylamide 1 mm hand-cast gel with varying volumes of lysate/Laemlli (5:1 ratio) buffer resulting in 15 μg of total cellular protein being loaded into each lane. Electrophoresis was executed at 60 V for 30 min followed by 1.5 h at 150 V. Electrophoresed gels along with extra thick blot paper and 0.2 μm pore-sized nitrocellulose membranes were allowed to equilibrate in transfer buffer containing 10% (v/v) methanol for 30 min before transfer. Transfer was executed using semidry consumables and the Turbo-blot transfer system (Bio-rad, Gladesville, New South Wales, Australia) set to 40 min at 25 V and 1.0 A. Transferred membranes were then rinsed briefly in TBS-T and then incubated in~20 mL of Licor blocking buffer at room temperature for 1 h. Membranes were again rinsed briefly in TBS-T and then incubated with a 1:500 dilution of the C219 antibody in TBS-T overnight. The β-actin antibody was added to the incubation solution for only the final 20 min of the overnight primary antibody incubation step, to avoid saturation of the actin signal at a dilution of 1:10,000. Following 4 × 10 min membrane washes in TBS-T, the membranes were incubated in Licor goat-anti-mouse secondary antibodies for 2 h at room temperature followed by the same washing regime as above. Membranes were scanned on the Licor Odyssey imaging instrument, and densitometric analysis was executed via the ImageJ software. Densitometric P-gp signals were normalised to β-actin signals and expressed as relative fold-changes to controls.
Influence of CQ/Zn 2+ /Cu 2+ on P-gp Function Assessed by R123 Trafficking hCMEC/D3 cells were seeded onto two separate 24-well collagen-coated plates at a density of 30,000 cells/cm 2 and left to grow in 500 μL of EBM2 growth media until they had reached 70-80% confluency. Plate 1 was used for the analysis of R123 uptake and plate 2, processed in parallel until the final 10 min of experimentation, was used for the determination of R123 efflux. Upon reaching 70-80% confluency, cells were treated with either (1) no treatment (control) or (2) 0.5 μM CQ, 0.1 μM Zn 2+ and 0.1 μM Cu
2+
. Each of these treatment conditions contained 0.1% DMSO and each were administered in an identical fashion to replicates occurring on both plates. After a 24 h incubation, the uptake/efflux experimental protocol was commenced; all solutions were removed and the wells were rinsed twice with 500 μL of pre-warmed PBS. Following rinsing, the cells were then re-incubated in transport buffer (10 mM HEPES in HBSS, pH = 7.40), or transport buffer containing 5 μM PSC833 (a known P-gp inhibitor), for 15 min on a shaker platform. After 15 min the wells were rinsed once with 500 μL/well of transport buffer, which was then replaced with 500 μL of transport buffer (± 5 μM PSC833) with the addition of 5 μM of the known P-gp substrate R123. Both plates (still effectively identical at this stage) were then left on gentle shaking inside an incubator for 60 min. After 60 min, the experimental processing of the two plates diverged; plate 1 (R123 uptake) was rinsed three times with 500 μL per well of ice-cold transport buffer before being immediately lysed with ice-cold transport lysis solution (1% v/v Triton X-100 in MilliQ water), for 20 min and on gentle agitation at 4°C. After 20 min, the fluorescence of R123 in each individual well was measured using an Enspire fluorescence spectrophotometer (PerkinElmer, Waltham, MA), with an excitation wavelength of 511 nm and an emission wavelength of 534 nm. The unknown concentrations of R123 were determined by comparison to standard solutions of known R123 concentrations which were prepared in the same matrix (1% v/v Triton X-100 in milliQ water) on the day of the uptake experiments. Immediately after the fluorescence was measured, two 20 μL aliquots from each well were removed and dispensed onto a non-sterile 96 well plate for protein content analysis. This new 96-well plate was then processed and compared to a freshly prepared standard curve for protein quantification using a BCA protein kit and BSA dissolved in the same matrix used as standards, and these values were later used to normalise R123 content in individual wells. The wells in plate 2 (R123 efflux) were then also rinsed three times with 500 μL per well of ice-cold transport buffer, before being re-incubated in transport buffer (± 5 μM PSC833) for a further 10 min, again on gentle agitation. After this 10 min period, all wells in the plate were subjected to the same lysing protocol as described for plate 1, before the measurement of R123 fluorescence and determination of protein content (described above). The experiment was executed in such a way that both plates 1 and 2 received identical treatments with respect to time, excluding the 10 min efflux phase (plate 2 only). The R123 fluorescence values from the accumulation plates were first normalised by well specific protein content, and then expressed as a percentage relative to the control replicates. The data from the efflux plates were expressed as the percentage of R123 remaining after efflux, relative to the accumulation control wells.
Assessment of hCMEC/D3 Cellular Translocation of Zn 2+ and Cu 2+ by CQ Treatment
To identify whether treatment of hCMEC/D3 cells with CQ and different metal combinations resulted in enhanced cellular uptake of metals, the concentrations of Cu and Zn were measured by inductively coupled plasma mass spectrometry (ICP-MS). hCMEC/D3 cells were seeded onto two separate 24-well collagen-coated plates at a density of 30,000 cells/cm 2 and left to grow in 500 μL of EBM2 growth media until they had reached 70-80% confluency. Cells were then treated with the same treatment regime as was used for assessing P-gp expression above (individual and combinatorial treatments of CQ, Zn 2+ and Cu
) in FBS free media for 24 h. After 24 h of treatment (or alternative time points as illustrated in results figures), the media was removed and cells were rinsed twice with sterile PBS to wash out any plastic-bound metal ions, before the addition of 250 μL per well of 1% Triton X-100 in PBS. Lysis was carried out exactly as was described for western blotting (including protein quantification for normalisation), except for the omission of the cellular-debris removing centrifuge step, but including the removal of a 20 μL aliquot for protein quantification by the BCA assay, to later be used for normalising data against well-to-well variability in cell density. Samples were stored at −80°C until analysis by ICP-MS. After freeze-drying the samples, each lyophilised cell crude extract was resuspended by adding 30 μL of concentrated nitric acid 65% (Suprapur Merck, Darmstadt, Germany) and allowed to digest for 6 h at room temperature. The samples were heated at 90°C for 20 min using a heating block to complete the digestion. The reduced volume after digestion was~20 μL. Each sample was made up to 1.150 mL by the addition of 1.130 mL of 1% (v/v) of nitric acid diluent. Measurements were made with an Agilent 7700 series ICP-MS instrument (Agilent Technologies, Santa Clara, CA) under routine multi-element operating conditions using a Helium Reaction Gas Cell. The instrument was calibrated using 0, 5, 10, 50, 100 and 500 ppb of certified multielement ICP-MS standard calibration solutions (ICP-MS-C A L 2 -1 , I C P -M S -C A L -3 a n d I C P -M S -C A L -4 , AccuStandard, New Haven, CT) for a range of elements. A certified internal standard solution containing 200 ppb of Yttrium (Y89) as an internal control (ICP-MS-IS-MIX1-1, Accustandard, New Haven, CT) was used for internal calibration. For each individual treatment tested, wells containing no cells were also incubated in treatment solutions, and underwent the same procedure as just described, such that background signal caused by treatment/plastic contamination was quantified, and averages of these controls were subtracted from actual experimental metal concentrations. The remaining metal concentrations were then multiplied by the lysis volume (230 μL) to reach a molar quantity of metal ions, and then normalised by the protein content of each well measured during lysis, and resultantly expressed as nmol (metal)/ mg of protein, according to Eq. 2:
where [cellular metal] = the metal concentrations in treated cell samples determined by ICP-MS, [blank metal] = the metal concentrations in samples derived from wells which received treatment but contained no cells, V = the volume of lysis buffer after the removal of protein content sample (0.00023 L), and protein = protein mass per well determined by the BCA assay, used here to normalise against well-to-well variability in cell density.
Statistical Comparisons
All data were visualised and statistically analysed using the Prism Graphpad Version 7 software. All comparisons between two groups were assessed by Student's t-test, whilst all experiments involving more than two groups, were assessed by one-way analysis of variance (ANOVA), with multiple comparisons assessed by Dunnett's test, or Tukey's test in the case of ICP-MS. Differences between groups were considered significant if the generated p values fell below 0.05. /Cu 2+ could be assessed for modulation of P-gp, the toxicity of each agent individually and in combination against the hCMEC/D3 cell line had to first be assessed, so as to not unintentionally deliver toxic concentrations and induce P-gp upregulation by generic cellular defence mechanisms. Toxicity in this regard was assessed via the use of the MTT reagent alongside morphological assessment of the cells via microscopy. Each component of CQ, Zn 2+ and Cu 2+ was assessed over the concentration range of 0.1 to 10 μM. As shown in Fig. 1a and c, low concentrations of both CQ (0.1 and 0.5 μM) and Cu 2+ (0.1 μM) actually stimulated metabolism of the MTT reagent (proxy for cell viability), causing 36 and 23% increases in formazan production, respectively. On these same figures it is observed that the highest concentrations of CQ and Cu 2+ which did not induce detectable toxicity were 0.5 and 1 μM respectively. Figure 1b shows cell viability following Zn 2+ treatment, and indicates that the cells tolerated the addition of Zn 2+ up to a concentration of 1 μM.
RESULTS
Identification of Combinatorial CQ/Zn
Representative images from the morphological assessment are shown in Fig. 1d , e, f and are concordant with the results generated by the MTT assay, whereby cells treated with 0.5 μM of CQ (Fig. 1e) appear as normal compared to control cells, but in contrast those treated with 10 μM of CQ (Fig. 1f) , alone or in combination, were able to enhance P-gp expression in hCMEC/D3 cells. The highest non-toxic concentrations that were tolerated by the hCMEC/D3 cell line (both alone and in combination) were identified as 0.5 μM CQ, 0.5 μM Zn 2+ and 0.1 μM Cu 2+ via the MTT assay and morphological assessment. As shown in Fig. 2a and b , the only treatment group to significantly increase P-gp expression relative to control group after analysis via a Dunnett's one-way ANOVA, was the combination of all three components: CQ (0.5 μM), Zn 2+ (0.5 μM) and Cu 2+ (0.1 μM), which produced a 1.7-fold increase in P-gp abundance (p = 0.0045). Since each of the components (CQ, Zn 2+ and Cu
2+
) when tested alone had no significant effect on P-gp expression, this result indicated that the presence of CQ and both metal ions may be required for significant upregulation of P-gp. The influence of this treatment group on P-gp expression was then assessed by western blotting, to confirm the observed upregulation, and as shown in Fig. 2c, d , this combination produced a significant 1.8-fold upregulation of P-gp abundance (p = 0.043), similar to that observed with the ICW approach. All further studies assessing the influence of CQ/Zn 2+ /Cu 2+ on hCMEC/D3 dynamics were undertaken with this particular combination. Since P-gp is expressed and subsequently localised in two distinct regions of brain endothelial cells, namely, the outer cell membrane and the lysosomal membrane (25) , an assay utilising the known P-gp substrate R123 was used concomitantly, to ensure that any increase in P-gp expression resulted in increased cellular efflux capacity. Figure 3a illustrates the relative cytosolic accumulation of R123 after a 1 h incubation with the substrate in the presence or absence of the known Pgp inhibitor PSC833. The presence of PSC833 induced a 36% increase in R123 accumulation, whilst pre-incubation for 24 h with CQ (0.5 μM), Zn 2+ (0.5 μM) and Cu
(0.1 μM) produced a 23% decrease in R123 accumulation. The inhibitory effect of PSC833 on R123 accumulation was offset by pre-incubation with CQ (0.5 μM), Zn 2+ (0.5 μM) and Cu 2+ (0.1 μM). After the accumulation phase, cells were presented with empty transport buffer (± PSC833) and allowed to efflux the substrate for 10 min before additional measurements were made, to demonstrate substrate flux in a bidirectional capacity. As shown in Fig. 3b, 32% of the initial R123 load remained in control cells, whilst PSC833 incubated cells retained 56% of the initial substrate load due to P-gp inhibition. The cells pre-treated with the CQ/Zn 2+ /Cu 2+ combination however, retained significantly less R123 than control cells (23%), signifying a functional enhancement of P-gp activity in both reducing cellular accumulation of and increased efflux capacity of the R123 substrate. These findings indicate that the induction of P-gp was effective in a bidirectional capacity.
CQ Increases Intracellular Copper but Not Zinc, Measured by Inductively-Coupled Plasma Mass Spectrometry
As a part of identifying the mechanism by which CQ and metal ions were able to facilitate upregulation of Pgp, ICP-MS was employed to measure changes in cellular metal levels (zinc and copper) resulting from the same treatment regime as was assessed for P-gp upregulation above. Despite the complex experimental design and notable intra-treatment noise, three treatment groups (Cu 2+ , CQ/Cu 2+ and CQ/Zn 2+ /Cu 2+ ) produced significant increases in cytosolic copper levels when compared to the control group via Tukey's test (Fig. 4a) . No significant differences between the Cu 2+ treatment and the P-gp upregulating combination (CQ/Zn 2+ /Cu 2+ ) treatment groups were determined (p = 0.12, bars 4 and 7), however this comparison was hindered by the large study design, and was resolved in subsequent experiments. The same ICP-MS analyses albeit for zinc is depicted in Fig. 4b . None of the eight treatment groups were able to significantly increase cytosolic zinc levels, suggesting that the observed effects of the CQ/Zn 2+ /Cu 2+ enhancing P-gp expression and function, are unlikely to be mediated by effects by Zn 2+ , but rather by Cu 2+ . To gain further insight into CQ-mediated mechanisms of P-gp upregulation, the kinetics of free versus CQ-mediated copper uptake into hCMEC/D3 cells were assessed in parallel. Figure 5 shows free copper (in blue) increasing marginally over time, whilst CQ-mediated copper uptake (shown in red) resulted in a significantly larger copper increase, but only the final time point assessed (24 h). Taken together, this set of ICP-MS experiments indicate that whilst endogenous copper uptake mechanisms are apparent in hCMEC/D3 cells, CQ administered in combination with copper can enhance the delivery of copper to intracellular regions, as was hypothesised, presumably via the metal ionophore activity described above, although the significant increases of cytosolic copper mediated by this ionophore are only visible after 24 h. DISCUSSION P-gp plays an important role in many life science applications and disease states, and understanding the biological inputs modulating the expression and activity of P-gp is a valuable endeavour. Whilst it has been shown that biometals such as zinc and copper can influence the barrier like properties of the endothelium (18) (19) (20) (21) , the effects of metal ions on barrier transporter proteins such as P-gp are relatively unknown. This study attempted to identify whether enhanced uptake of either of the biometals zinc or copper by ionophoric delivery via the use of CQ could result in modulation of P-gp expression and/ or activity.
To investigate this aim, the relative expression of P-gp was measured in an ICW assay, performed in the immortalised hCMEC/D3 cell line. This ICW approach has been validated previously by comparing modulated P-gp expression results with those derived from WB, after treatment with several known P-gp regulating compounds (24) . The results from the ICW in this study indicated that only the combination of 
CQ, Zn
2+ and Cu 2+ (0.5, 0.5 and 0.1 μM) produced a statistically significant upregulation (1.7-fold) of P-gp expression. Use of the fluorescent P-gp substrate R123 showed that treating hCMEC/D3 cells for 24 h with the combination just described induced a reduction in R123 accumulation, and an increase in post-R123-loading efflux, indicating that the activity of P-gp had been functionally enhanced. This effect of P-gp functional enhancement was negated when cells were cotreated with the known P-gp inhibitor PSC833, indicating specific modulation of P-gp. These results were also confirmed by WB, which indicated a concordant 1.8-fold increase in Pgp expression. Previous studies have demonstrated links between biometal treatment and BBB integrity, barrier function, endothelial viability and angiogenesis in both in vitro, as well as murine and porcine in vivo systems (18) (19) (20) (21) . Since it has been shown elsewhere that tight junction proteins essential for barrier formation and function, and the expression for transporters like P-gp are both under the influence of similar signalling pathways (26, 27) , these findings of enhanced expression and function of P-gp via biometal delivery are consistent with the other experimental evidence available.
Investigation of biometal uptake into the endothelial cell line by ICP-MS revealed that despite the combination of CQ/ Zn 2+ /Cu 2+ being required to achieve significant upregulation of P-gp, cytosolic zinc levels were not affected in the experimental paradigm used (Fig. 4b) , indicating that zinc may not play a major role in the observed endothelial upregulation of P-gp. Treatment with copper alone (0.1 μM CuCl 2 ) was able to significantly increase levels of cytosolic copper from approximately 0.6 ± 0.2 nmol/mg of protein to 1.6 ± 0.6 nmol/mg of protein (Fig. 4a ), but this increase did not appear to drive an increase in P-gp expression in the experimental paradigm that was explored (Fig. 1a) . Under normal physiological conditions, BBB uptake of zinc and copper are mediated and regulated by endogenous biometal transporter proteins, divalent metal transporter 1 (DMT1; both zinc and copper) (28) , and copper transporter 1 (CTR1; copper only) (28) . The rate and extent of copper uptake however, is mediated by CTR1 expression, which has been shown to become downregulated by endothelial cells in the presence of relatively higher extracellular concentrations of copper, by a process of internalisation and recycling of the CTR1 transporter (29) . Cytosolic protein- mediated copper storage mechanisms also function within cells, to limit the biologically available copper and thus prevent toxicity (30) . Therefore, therapeutically enhanced delivery of copper to cellular interiors might be required to drive the desired copper-mediated protein signalling and expression, such as the upregulation of P-gp. The use of the ionophore compound CQ appears to have achieved this aim. As assessed by ICP-MS, treatment of hCMEC/D3 cells with CQ/Cu 2+ and CQ/Zn 2+ /Cu 2+ increased cytosolic copper to 2.2 ± 1.1 and 2.6 ± 0.9 nmol/mg of protein respectively (Fig. 4a) . Whilst these average increases (compared to the 0.1 μM Cu 2+ treatment group value of 1.6 ± 0.6 nmol/mg of protein) did not reach statistical significance due to the large study design, subsequent experiments were able to resolve this difference. When time-dependent copper uptake in hCMEC/ D3 cells was measured in a separate experiment as shown in Fig. 5 , CQ-mediated copper delivery was observed as significantly enhanced at the 24-h time point when compared to uptake of free copper alone, but not in earlier time-point measurements (3.2 ± 1 vs 1.5 ± 0.6 nmol/mg of protein respectively). This experiment demonstrates that while endogenous endothelial copper uptake is rate and extent limited, copper delivery to cell interiors can be enhanced by the use of biometal ionophores such as CQ.
Whilst encouraging, the data presented herein are subject to some limitations. Firstly, due to the high proportion of protein binding (31) , it was required for CQ to be administered to cells in serum free media, which represents a divergence from physiological conditions, where proteins appear ubiquitously in all biological fluids and will most likely interact with CQ in vivo. Additionally, the lysis protocol used for the generation of the ICP-MS data was designed intentionally to leave the cells largely intact, and thus to observe and quantify only cytosolic and cytosolically protein-bound biometals in our analysis. As a result, any biometals that were taken up by the cells and immediately utilised for cellular processes such as incorporation into plasma membrane bound proteins, etc. may not have been measured in our experiments, potentially leading to an underestimation of biometal uptake, in the case of both endogenous and CQ-mediated copper uptake.
Despite these limitations, we find that the data presented in this study provides firm ground upon which to base further experiments. Most obvious is the need to identify the mechanism by which increased intracellular copper is able to drive Pgp expression. Copper interacts with a host of cell proteins (32) , some of which may be upstream of P-gp expression signalling mechanisms. Cu 2+ has also been shown to inhibit glycogen synthase kinase 3 (22) , a signalling molecule which has been demonstrated to be an integral part of the Wnt/β-catenin signalling pathway that serves as one input for P-gp expression (33, 34) , and which has been reported to be functional in hCMEC/D3 cells (34) . Another possibility is the stabilisation of P-gp at the plasma membrane. Normally, Pgp exhibits the presence of a divalent magnesium ion, the concentration of which influences marginal control over Pgp stability and activity, but which is not essential for P-gp activity (35) . An increase of Cu 2+ ion influx through the plasma membrane might have the potential to displace Mg 2+ ions, subsequently stabilising P-gp at the plasma membrane. Studies to elucidate the mechanism of CQ/Cu 2+ mediated upregulation of P-gp are currently underway, alongside investigations in animal models, to interrogate the broader context of the in vitro findings observed within this study.
These studies have highlighted that CQ together with biometals, can increase the expression and function of P-gp in BBB phenotypical cells. It is possible, therefore, that part of the Aβ-lowering effects of CQ reported previously (23, 36) may result from increased BBB efflux of Aβ, since Aβ is a substrate of P-gp, although further studies to confirm this hypothesis are required to be undertaken. Furthermore, this study has revealed a potential role of Cu 2+ in regulating the expression and function of P-gp at the BBB, which is a novel finding. Given that P-gp is a major hindrance to the CNS entry of many therapeutic agents intended to reach the brain, it is possible that intentional manipulation of brain endothelial cell Cu 2+ levels could be exploited to reduce P-gp expression and enhance CNS delivery of drugs which are substrates of P-gp. In addition, drugs such as CQ which modulate the brain endothelial cell levels of Cu 2+ have the potential to result in interactions with drugs which are substrates of P-gp, as the enhanced P-gp expression mediated by CQ could reduce the CNS entry of drugs with high affinity to P-gp.
CONCLUSION
When co-administered with copper at nanomolar concentrations, CQ is able to produce significant upregulation of P-gp, in an immortalised human cerebral microvascular endothelial cell line. Enhanced P-gp expression appears to be associated with increased intracellular copper uptake, and future studies will interrogate the mechanism mediating the increase of this important efflux transporter, along with the biological relevance of these findings within in vivo systems.
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